SMMT
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Phase 3 HARMONi-GI1 trial of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first-line advanced biliary tract cancer will be featured at the ESMO 2026 Presidential SymposiumSep 22, 2026
- Global Phase 3 HARMONi primary analysis results for ivonescimab plus chemotherapy were published in The Lancet OncologyAug 25, 2026
- Ivonescimab plus chemotherapy was approved in China by the NMPA for first-line treatment of patients with squamous non-small cell lung cancerAug 12, 2026
- Summit Therapeutics and Arcus Biosciences partner to evaluate ivonescimab with casdatifan in kidney cancerJul 23, 2026
- Summit Therapeutics signed an agreement to sell its Phase 3 asset Ridinilazole to BiossilJul 14, 2026